Skip to main content

Table 2 Schedule of assessments

From: The efficacy of behavioural activation treatment for co-occurring depression and substance use disorder (the activate study): a randomized controlled trial

Domain Measure Screening Baseline
Pre-allocation
3 month follow-up 12 month
Follow-up
Eligibility
Depression symptoms Patient Health Questionnaire (PHQ-9) [56] +
Depression screener CIDI 3.0 Depression screener questions [54, 55] +
Primary outcome measures
Substance dependence CIDI 3.0 Substance dependence
(past month DSM-IV TR) [54]
Severity of Dependence Scale (SDS) [61]

+
+
+
+
+
+
Depression CIDI 3.0 Major depression
(past month DSM-IV TR) [54, 55]
Beck Depression Inventory-II (BDI-II) [49]

+
+
+
+
+
+
Secondary outcome measures
Behavioural activation Behavioural Activation for Depression Scale Short Form (BADS-SF; [70]) + + +
Anxiety Beck Anxiety Inventory (BAI; [71]) + + +
Social phobia CIDI 3.0 Social Phobia (past month DSM-IV-TR) [54]
Liebowitz Social Anxiety Scale [72, 73]

+
+
+
+
+
+
Traumatic events & trauma symptoms PTSD trauma checklist from the CIDI 3.0 [54] and the Post-Traumatic Stress Disorder Checklist – Civilian Version (PCL-C; [74]) - + + +
Borderline Personality Disorder International Personality Disorders Examination (IPDE; [75]) + + +
Environmental Reward Environmental Rewards Observation Scale (EROS; [76]) + + +
Rumination Perseverative Thinking Questionnaire (PTQ; [77, 78]) and Ruminative Response Scale (RRS; [79]) + + +
Distress Tolerance Distress Tolerance Scale (DTS; [80]) + + +
Sleep disturbance Pittsburgh Sleep Quality Index (PSQI; [81]) + + +
Chronic physical conditions As outlined by the Australian National Health Priority Area [82, 83] + + +